<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202020000300133</article-id>
<article-id pub-id-type="doi">10.29277/cardio.35.3.11</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Lo mejor del Congreso 2020 de la Sociedad Europea de Cardiología: la experiencia digital]]></article-title>
<article-title xml:lang="en"><![CDATA[The best of the 2020 European Society of Cardiology Congress: the digital experience]]></article-title>
<article-title xml:lang="pt"><![CDATA[O melhor do Congresso da Sociedade Europeia de Cardiologia 2020: a experiência digital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ache]]></surname>
<given-names><![CDATA[Yamel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guamán]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[María Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Cardiológico Americano  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Clínicas Centro Cardiovascular Universitario ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Cardiovascular Casa de Galicia  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>133</fpage>
<lpage>172</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202020000300133&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202020000300133&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202020000300133&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La necesidad de distanciamiento social impuesta por la actual pandemia por coronavirus obligó a las diferentes sociedades científicas a realizar sus actividades en formato completamente virtual. La Sociedad Europea de Cardiología no ha sido la excepción. Desde el 29 de agosto al 1 de septiembre de 2020 se celebró este evento sin precedentes que, además de contar con 125.000 profesionales de 213 países, permitió el acceso gratuito a todos los cibernautas. De esta manera, la actualidad en cardiología pudo llegar a todos los rincones del mundo, pese a las circunstancias tan complejas. Como ya es tradición de la revista, realizamos un resumen de los principales ensayos presentados durante el congreso:    - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)  - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators)  - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)  - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial)  - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD)  - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A))  - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators)  - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC)  - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial)  - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary The need for social distancing imposed by the current coronavirus pandemic, forced the different scientific societies to carry out their activities in a completely virtual format. And the European Society of Cardiology has not been the exception. From August 29 to September 1 of 2020, this unprecedented event was held which, in addition to having 125,000 health professionals from 213 countries, allowed free access to all netizens. In this way, current affairs in cardiology could reach all corners of the world, despite such complex circumstances. As is the tradition of the magazine, we present a summary of the main essays presented during the congress:    - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)  - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators)  - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)  - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial)  - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD)  - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A))  - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators)  - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC)  - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial)  - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A necessidade de distanciamento social imposto pela atual pandemia do coronavírus, obrigou as diferentes sociedades científicas a desenvolverem suas atividades de forma totalmente virtual. E a Sociedade Europeia de Cardiologia não foi exceção. De 29 de agosto a 1º de setembro 2020, foi realizado esse evento inédito que, além de contar com 125.000 profissionais de saúde de 213 países, possibilitou o acesso gratuito a todos os internautas. Dessa forma, a atualidade da cardiologia pode atingir todos os cantos do mundo, apesar de circunstâncias tão complexas. Como é tradição da revista, apresentamos um resumo dos principais ensaios apresentados durante o congresso:    - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)  - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators)  - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)  - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial)  - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD)  - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A))  - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators)  - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC)  - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial)  - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[EAST-AFNET 4]]></kwd>
<kwd lng="es"><![CDATA[EMPEROR]]></kwd>
<kwd lng="es"><![CDATA[EXPLORER-HCM]]></kwd>
<kwd lng="es"><![CDATA[PARALLAX]]></kwd>
<kwd lng="es"><![CDATA[DAPA-CKD]]></kwd>
<kwd lng="es"><![CDATA[POPULAR-TAVI]]></kwd>
<kwd lng="es"><![CDATA[LODOCO2]]></kwd>
<kwd lng="es"><![CDATA[BPLTTC]]></kwd>
<kwd lng="es"><![CDATA[BRACE CORONA]]></kwd>
<kwd lng="es"><![CDATA[REALITY]]></kwd>
<kwd lng="en"><![CDATA[EAST-AFNET 4]]></kwd>
<kwd lng="en"><![CDATA[EMPEROR]]></kwd>
<kwd lng="en"><![CDATA[EXPLORER-HCM]]></kwd>
<kwd lng="en"><![CDATA[PARALLAX]]></kwd>
<kwd lng="en"><![CDATA[DAPA-CKD]]></kwd>
<kwd lng="en"><![CDATA[POPULAR-TAVI]]></kwd>
<kwd lng="en"><![CDATA[LODOCO2]]></kwd>
<kwd lng="en"><![CDATA[BPLTTC]]></kwd>
<kwd lng="en"><![CDATA[BRACE CORONA]]></kwd>
<kwd lng="en"><![CDATA[REALITY]]></kwd>
<kwd lng="pt"><![CDATA[EAST-AFNET 4]]></kwd>
<kwd lng="pt"><![CDATA[EMPEROR]]></kwd>
<kwd lng="pt"><![CDATA[EXPLORER-HCM]]></kwd>
<kwd lng="pt"><![CDATA[PARALLAX]]></kwd>
<kwd lng="pt"><![CDATA[DAPA-CKD]]></kwd>
<kwd lng="pt"><![CDATA[POPULAR-TAVI]]></kwd>
<kwd lng="pt"><![CDATA[LODOCO2]]></kwd>
<kwd lng="pt"><![CDATA[BPLTTC]]></kwd>
<kwd lng="pt"><![CDATA[BRACE CORONA]]></kwd>
<kwd lng="pt"><![CDATA[REALITY]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Muntner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bittencourt]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Callaway]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics - 2019 update a report from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>139</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e56-528</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wyse]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Waldo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[DiMarco]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Domanski]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Schron]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of rate control and rhythm control in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1825-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Denus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sanoski]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Opolski]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spinler]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rate vs rhythm control in patients with atrial fibrillation a metaanalysis]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2005</year>
<volume>165</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>258-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corley]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[DiMarco]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Domanski]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Geller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>109</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1509-13</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bunch]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Bair]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Crandall]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2013</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1257-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of atrial fibrillation on the risk of death the Framingham Heart Study]]></article-title>
<collab>D'Agostino RB.Silbershatz H.Kannel WB.Levy D</collab>
<source><![CDATA[Circulation]]></source>
<year>1998</year>
<volume>98</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>946-52</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goette]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brandes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Elvan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early rhythm-control therapy in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mosenzon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Zelniker]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Furtado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>139</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2528-36</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kober]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with heart failure and reduced ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>1995-2008</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filipatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="confpro">
<source><![CDATA[Hot Line EMPEROR-Reduced]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress, The Digital Experience]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical course and management of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<page-range>655-68</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borggrefe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Charron]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hagege]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lafont]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<collab>Authors/Task Force members</collab>
<article-title xml:lang=""><![CDATA[2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>2733-79</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heitner]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Jacoby]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy A Clinical Trial]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2019</year>
<volume>170</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>741-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Oreziak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barriales-Willa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Masri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Pavia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="confpro">
<source><![CDATA[PARALLAX meets one primary endpoint in heart failure with preserved ejection fraction]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Phil]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>1609-20</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction - PARALLAX]]></article-title>
<source><![CDATA[American College of Cardiology]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="confpro">
<source><![CDATA[Hot Line PARALLAX. Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress, The Digital Experience]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PARALLAX: Sacubitril/Valsartan Compared with Optimized Background Therapy in HFpEF Patients]]></article-title>
<source><![CDATA[American College of Cardiology]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (Dapa-CKD)]]></article-title>
<source><![CDATA[ClinicalTrials.gov]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="confpro">
<source><![CDATA[DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="confpro">
<source><![CDATA[Dapagliflozin in Patients with Chronic Kidney Disease DAPA-CKD]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress 2020 The Digital Experience]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hildick-Smith]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Durand]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kikkert]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wiegerinck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Stabile]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiplatelet therapy following transcatheter aortic valve implantation]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2015</year>
<volume>101</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1118-25</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montalto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pagnesi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Regazzoli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ancona]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2017</year>
<volume>119</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1088-93</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nijenhuis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Delewi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hermanides]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Holvoet]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Everett]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Thuren]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[MacFayden]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ballantyne]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiinflamatory therapy with canakinummab for atherosclerotic disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<page-range>1119-31</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kouz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Waters]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrand]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of low-dose colchicine after myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>2497-505</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nidorf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Budgeon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose colchicine for secondary prevention of cardiovascular disease]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>61</volume>
<page-range>404-10</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nidorf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fiolet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mosterd]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schut]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Opstal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colchicine in patients with chronic coronary disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="confpro">
<source><![CDATA[Hot Line LoDoCo2. Colchicine in Patients with Chronic Coronary Disease]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress 2020 The Clinical Experience]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Blood Pressure Lowering Treatment Trialists' Collaboration]]></article-title>
<source><![CDATA[N.d.BPLTTC]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahimi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacological blood pressure-lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant meta-analysis of 48 randomized clinical trials and 348,854 participants]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC]]></article-title>
<source><![CDATA[TCTMD]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Junqueira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) - The BRACE CORONA Trial]]></article-title>
<collab>D'Andréa G</collab>
<source><![CDATA[Am Heart J]]></source>
<year>2020</year>
<volume>226</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="confpro">
<source><![CDATA[First randomized trial backs safety of common heart drugs in COVID-19 patients. BRACE CORONA trial presented in a Hot Line Session]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers - BRACE CORONA]]></article-title>
<source><![CDATA[American College of Cardiology]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[BRACE CORONA: Does Temporarily Suspendin RAAS Inhibitors Show Clinical Benefit in Hospitalized COVID-19 Patients?]]></article-title>
<source><![CDATA[American College of Cardiology]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="confpro">
<source><![CDATA[BRACE CORONA: Continuing versus Suspending ACE Inhibitors and ARBs in COVID-19]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress 2020 The Digital Experience]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of hemoglobin levels with clinical outcomes in acute coronary syndromes]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>111</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>2042-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Wimmer]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood transfusion in myocardial infarction opening old wounds for comparative-effectiveness research]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>64</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>820-2</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wetterslev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lichstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mukherjee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of blood transfusion with increased mortality in myocardial infarction a meta-analysis and diversity-adjusted study sequential analysis]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2013</year>
<volume>173</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-9</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silvain]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cayla]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brieger]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bellemain-Appaix]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chastre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers results of the TRANSFUSION study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2816-21</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="confpro">
<source><![CDATA[REALITY - A Trial of Transfusion Strategies for Myocardial Infarction and Anemia in a Hot Line Session]]></source>
<year></year>
<conf-name><![CDATA[ ESC Congress]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
